Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Fabre-Kramer Pharmaceuticals Inc.
DescriptionPartial agonist serotonin (5-HT1A) receptor
Molecular Target Serotonin (5-HT1A) receptor
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationAnxiety
Indication DetailsTreat generalized anxiety disorder (GAD)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today